Brief Title
Pegvisomant And Sandostatin LAR Combination Study
Official Title
A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly
Brief Summary
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
Number of subjects experiencing treatment-emergent adverse events across the duration fo the study
Secondary Outcome
Percentage of patients with normalization of IGF-I, at Week 40, in the two randomized groups (Sandostatin LAR plus pegvisomant and pegvisomant alone). Normal IGF-I is defined as a value within the normal reference range for age for the study specific
Condition
Acromegaly
Intervention
Pegvisomant/ Sandostatin LAR
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
75
Start Date
October 2003
Completion Date
May 2006
Eligibility Criteria
Inclusion Criteria: - Diagnosis of acromegaly - Received previous radiation and/or surgical treatment for their GH (Growth Hormone) producing pituitary adenoma and have required medical therapy due to failure to normalize GH (Growth Hormone) and/or IGF-I as a result of their primary treatment - Patients that been receiving Sandostatin LAR for a minimum of 6 months prior to enrollment Exclusion Criteria: - Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations - Patients on current medical therapy other than Sandostatin LAR - AST/ALT >= 3xULN (upper limits of normal) - Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI - Visual field defects (except post-surgical stable residual defects) - Unable to self administer drug - Radiotherapy within 12 months of entering the study
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Pfizer CT.gov Call Center, ,
Location Countries
Australia
Location Countries
Australia
Administrative Informations
NCT ID
NCT00068029
Organization ID
PEGA-0435-005
Secondary IDs
A6291006
Study Sponsor
Pfizer
Study Sponsor
Pfizer CT.gov Call Center, Study Director, Pfizer
Verification Date
April 2008